A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006904/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate ORR (Objective Response Rate) of gefitinib as a
second-line therapy for NSCLC patients based on RECIST (Response Evaluation Criteria in Solid
Tumors Group) and check up ORR difference by EGFR mutation, gender, smoking history, and type
of tumor.
提供机构：
Vivli
创建时间：
2021-04-16
